To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00141414

Enrollment

Registered

2005-09-01

Start date

1997-11-30

Completion date

2005-10-31

Last updated

2007-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Partial

Brief summary

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Interventions

DRUGPregabalin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have met the inclusion criteria for preceding double-blind study. * Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

* Pregnant or considering becoming pregnant. * Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Germany, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026